Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury (Q46983870)

27 December 2017

title

Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury (English)

1 reference

27 December 2017

congenital plasminogen activator inhibitor type 1 deficiency

1 reference

1 reference

Ma J

1

1 reference

27 December 2017

Weisberg A

2

1 reference

27 December 2017

Griffin JP

3

1 reference

27 December 2017

Vaughan DE

4

1 reference

27 December 2017

Fogo AB

5

1 reference

27 December 2017

Brown NJ

6

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

27 December 2017

published in

Kidney International

1 reference

27 December 2017

volume

69

1 reference

27 December 2017

page(s)

1064-1072

1 reference

27 December 2017

issue

6

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000201

exact match

0 references

cites work

Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Mineralocorticoids, hypertension, and cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Biological determinants of aldosterone-induced cardiac fibrosis in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

PAI-1, fibrosis, and the elusive provisional fibrin matrix

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Plasminogen activator inhibitor-1 and the kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Selective adhesion of osteoblastic cells to different integrin ligands induces osteopontin gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Role of metabolism and receptor responsiveness in the attenuated responses to Angiotensin II in mice compared to rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000201

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000201

1 reference

27 December 2017

Dimensions Publication ID

0 references

1 reference

27 December 2017